Thomson Reuters, a distinguished brokerage company, has placed a 52-week price target of $60.22 on Valeant Pharmaceuticals International, Inc. The Weekly and Monthly Volatility of the stock are 7.76% and 7.44% respectively. This ratio, which is also called as the P/E ratio evaluates the company on relative expense factor.
Advertisement
Revenue – In terms of revenue, VRX also missed the mark. In dermatology in particular the company has experienced average selling prices that are negative and are essentially taping dollar bills to drugs as they go out the door.
05/26/2016 – Valeant Pharmaceuticals International, Inc. had its “underperform” rating reiterated by analysts at Wells Fargo. Stifel Nicolaus’ price target indicates a potential upside of 123.21% from the stock’s current price.
The Board of Directors of Bristol-Myers Squibb Company (BMY) recently reported a quarterly dividend of thirty-eight cents ($0.38) per share on the $.10 par value Ordinary Stock of the corporation. These big sellers will be the key to paying off Valeant stock’s debt.
Want the latest recommendations from Zacks Investment Research?
In a report released today, Liisa Bayko from JMP Securities maintained a Buy rating on Ultragenyx (NASDAQ: RARE), with a price target of $84. Candriam Luxembourg S.C.A. boosted its stake in shares of Valeant Pharmaceuticals Intl by 48.1% in the fourth quarter.
The difficulty has been mainly in getting reimbursement – something that used to be the specialty of Philidor, the pharmacy that previously handled the same products but that shut down previous year after a scandal erupted around its relationship to Valeant. The New York-based Brave Warrior Advisors Llc has invested 25.22% in the stock. Candriam Luxembourg S.C.A. now owns 27,011 shares of the specialty pharmaceutical company’s stock valued at $2,744,000 after buying an additional 8,768 shares during the last quarter.
Return on Investment for Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is 3.70% and on Tuesday its shares closed at $24.64. About 45.33 million shares traded hands or 29.59% up from the average. The company had $1.3 billion in cash as of March 31. The firm’s 50 day moving average is $30.13 and its 200-day moving average is $64.00. The shares registered one year high of $51.99 and one year low was seen at $16.64. Indeed, the poor results have not shaken the stock in the same way as the $600-million reporting mistake that caused a major plunge last March.
Advertisement
Adjusted earnings reported in US dollars were $442.6 million or $1.27 per share, down from $704.2 million or $2.05 per share in the first quarter of 2015. Revenue rose 9% to $2.37 billion, slightly below estimates. The majority of this revenue rise can be attributed to Valeant’s purchases past year, while in house business continued to exhibit a slow down; organic sales in 1QFY16 fell by nearly $289 million. However, revenues of $23.7 million were up from $21.7 million in the year-ago quarter and above the Zacks Consensus Estimate of $23.4 million. Equities analysts forecast that Valeant Pharmaceuticals Intl will post $8.18 earnings per share for the current year. The Company is engaged in developing manufacturing and marketing a range of branded generic and branded generic pharmaceuticals over-the-counter (OTC) products and medical devices (contact lenses intraocular lenses ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in over 100 countries.
